The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume 10, Issue 12, Pages 1363-1377
Publisher
Informa Healthcare
Online
2015-11-13
DOI
10.1517/17460441.2015.1094051
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir"
- (2015) G. J. Dore et al. CLINICAL INFECTIOUS DISEASES
- Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study
- (2015) Michael P. Curry et al. GASTROENTEROLOGY
- Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation
- (2015) Michael Charlton et al. GASTROENTEROLOGY
- Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
- (2015) Saleh A. Alqahtani et al. HEPATOLOGY
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
- (2015) Fred Poordad et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- From non-A, non-B hepatitis to hepatitis C virus cure
- (2015) Jean-Michel Pawlotsky et al. JOURNAL OF HEPATOLOGY
- Hepatitis C
- (2015) Daniel P Webster et al. LANCET
- A pill a day keeps HCV away
- (2015) Ivan Gentile et al. LANCET INFECTIOUS DISEASES
- New drug for hepatitis C contributes to 13% rise in spending on prescription drugs in US
- (2015) M. McCarthy BMJ-British Medical Journal
- New drug for hepatitis C contributes to 13% rise in spending on prescription drugs in US
- (2015) M. McCarthy BMJ-British Medical Journal
- Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C
- (2015) Alena M. Pfeil et al. PLoS One
- Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection
- (2014) R. S. Koff ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938
- (2014) Jeremie Guedj et al. ANTIVIRAL THERAPY
- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
- (2014) Evguenia S. Svarovskaia et al. CLINICAL INFECTIOUS DISEASES
- Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies
- (2014) Imran Shahid et al. CRITICAL REVIEWS IN MICROBIOLOGY
- Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency
- (2014) Floriano Rosina et al. DIGESTIVE AND LIVER DISEASE
- The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
- (2014) Gisa Gerold et al. DIGESTIVE DISEASES
- Sofosbuvir: First Global Approval
- (2014) Gillian M. Keating et al. DRUGS
- Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection
- (2014) Ivan Gentile et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus
- (2014) Ivan Gentile et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C
- (2014) Guido Stirnimann EXPERT OPINION ON PHARMACOTHERAPY
- Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
- (2014) Ivan Gentile et al. Expert Review of Anti-Infective Therapy
- New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
- (2014) Jean–Michel Pawlotsky GASTROENTEROLOGY
- Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
- (2014) Eric F. Donaldson et al. HEPATOLOGY
- Global distribution and prevalence of hepatitis C virus genotypes
- (2014) Jane P. Messina et al. HEPATOLOGY
- Treatment of Hepatitis C
- (2014) Anita Kohli et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
- (2014) Mark S. Sulkowski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Global epidemiology and genotype distribution of the hepatitis C virus infection
- (2014) Erin Gower et al. JOURNAL OF HEPATOLOGY
- A General and Enantioselective Approach to Pentoses: A Rapid Synthesis of PSI-6130, the Nucleoside Core of Sofosbuvir
- (2014) Manuel Peifer et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program
- (2014) S. Bruno et al. JOURNAL OF VIRAL HEPATITIS
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C treatment: an incipient therapeutic revolution
- (2014) Andrew S. deLemos et al. TRENDS IN MOLECULAR MEDICINE
- A Novel Promising Therapeutic Option Against Hepatitis C Virus: An Oral Nucleotide NS5B Polymerase Inhibitor Sofosbuvir
- (2013) I. Gentile et al. CURRENT MEDICINAL CHEMISTRY
- Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection
- (2013) N. Coppola et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection
- (2013) David Alan Herbst et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature
- (2013) Ferdinando Fusco et al. EXPERT OPINION ON PHARMACOTHERAPY
- Hepatitis C therapy with HCV NS5B polymerase inhibitors
- (2013) Vincent Soriano et al. EXPERT OPINION ON PHARMACOTHERAPY
- Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection
- (2013) Maribel Rodríguez-Torres Expert Review of Anti-Infective Therapy
- A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C
- (2013) Ivan Gentile et al. Hepatitis Monthly
- Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
- (2013) Donald B. Smith et al. HEPATOLOGY
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
- (2013) Adriaan J. van der Meer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics
- (2013) Anuoluwapo Osinusi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
- (2013) Kris V Kowdley et al. LANCET
- Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
- (2013) Eric Lawitz et al. LANCET
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
- (2013) Eric Lawitz et al. LANCET INFECTIOUS DISEASES
- Epidemiology and natural history of HCV infection
- (2013) Behzad Hajarizadeh et al. Nature Reviews Gastroenterology & Hepatology
- The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
- (2013) Ralf Bartenschlager et al. NATURE REVIEWS MICROBIOLOGY
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sustained virological response: A milestone in the treatment of chronic hepatitis C
- (2013) Filomena Morisco WORLD JOURNAL OF GASTROENTEROLOGY
- Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential
- (2013) Catherine Stedman Therapeutic Advances in Gastroenterology
- Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus
- (2012) Angela M. Lam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Pharmacodynamics, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor, following Multiple Ascending Doses in Patients with Chronic Hepatitis C Infection
- (2012) Eric Lawitz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects
- (2012) Jill Denning et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs
- (2012) Karolina Madela et al. Future Medicinal Chemistry
- Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial
- (2012) Maribel Rodriguez-Torres et al. JOURNAL OF HEPATOLOGY
- Hepatitis C virus—host interactions, replication, and viral assembly
- (2012) Ana Shulla et al. Current Opinion in Virology
- A New Evolutionary Model for Hepatitis C Virus Chronic Infection
- (2012) Rebecca R. Gray et al. PLoS Pathogens
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
- (2011) JOURNAL OF HEPATOLOGY
- New direct-acting antivirals' combination for the treatment of chronic hepatitis C
- (2011) Tarik Asselah et al. LIVER INTERNATIONAL
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PSI-7851, a Pronucleotide of -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication
- (2010) A. M. Lam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
- (2010) Alexander J. Thompson et al. GASTROENTEROLOGY
- Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977
- (2010) Eisuke Murakami et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Surrogate endpoints and non-inferiority trials in chronic viral hepatitis
- (2010) Ivan Gentile et al. JOURNAL OF HEPATOLOGY
- Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus
- (2010) Michael J. Sofia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
- (2010) Tarik Asselah et al. LIVER INTERNATIONAL
- Assembly of infectious hepatitis C virus particles
- (2010) Ralf Bartenschlager et al. TRENDS IN MICROBIOLOGY
- The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus
- (2009) Ivan Gentile et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial
- (2009) Ivan Gentile et al. JOURNAL OF CLINICAL APHERESIS
- An Efficient and Diastereoselective Synthesis of PSI-6130: A Clinically Efficacious Inhibitor of HCV NS5B Polymerase
- (2009) Peiyuan Wang et al. JOURNAL OF ORGANIC CHEMISTRY
- The global burden of hepatitis C
- (2009) Daniel Lavanchy LIVER INTERNATIONAL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now